Protara OKd to start Phase 2 study in pediatric lymphatic disorder

 

• STARBORN-1 trial leverages data from TARA-002 predecessor therapy OK-432, which is approved and has treated thousands of pediatric patients with Lymphatic Malformations in Japan and Taiwan as well as over 500 patients in a compassionate use study completed in the U.S.
• TARA-002 previously granted Rare Pediatric Disease Designation by the FDA for the treatment of Lymphatic Malformations
• Study startup activities ongoing; trial initiation expected in Q423

https://www.biospace.com/article/releases/protara-therapeutics-receives-regulatory-clearance-from-fda-to-commence-phase-2-starborn-1-trial-of-tara-002-in-pediatric-patients-with-lymphatic-malformations/